{
    "nctId": "NCT02371174",
    "briefTitle": "Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.",
    "officialTitle": "An Observational Post-Marketing Surveillance Study on the Status and Factors for the Development of Peripheral Neuropathy in Patients With HER2-Negative Inoperable or Recurrent Breast Cancer in Japan.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, HER2-negative Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 651,
    "primaryOutcomeMeasure": "Number of participants with adverse events and serious adverse events",
    "eligibilityCriteria": "Inclusion criteria:\n\nPatients with HER2-negative inoperable or recurrent breast cancer.\n\nExclusion criteria:\n\nPatients with high-grade bone marrow depression (absolute neutrophil count less than 1,000 /mm\\^3, absolute platelet count less than 75,000 /mm\\^3).\n\nPatients with a history of hypersensitivity to the ingredients of HALAVEN. Women who are pregnant or may be pregnant. Patients with a history of use of HALAVEN.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}